Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) heavily pretreated with anthracycline and taxanes. METHODS: In this single-arm, phase II study, patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hanfang, Li, Huiping, Song, Guohong, Di, Lijun, Shao, Bin, Yan, Ying, Liu, Xiaoran, Chen, Yifei, Zhang, Ruyan, Ran, Ran, Liu, Yaxin, Gui, Xinyu, Wang, Nan, Wang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986665/
https://www.ncbi.nlm.nih.gov/pubmed/36877215
http://dx.doi.org/10.1007/s10549-023-06894-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986665/
https://www.ncbi.nlm.nih.gov/pubmed/36877215
http://dx.doi.org/10.1007/s10549-023-06894-3

Ejemplares similares